Your browser doesn't support javascript.
loading
Myelodysplastic syndrome (MDS) with isolated trisomy 8: a type of MDS frequently associated with myeloproliferative features? A report by the Groupe Francophone des Myélodysplasies.
Drevon, Louis; Marceau, Alice; Maarek, Odile; Cuccuini, Wendy; Clappier, Emmanuelle; Eclache, Virginie; Cluzeau, Thomas; Richez, Valentine; Berkaoui, Inès; Dimicoli-Salazar, Sophie; Bidet, Audrey; Vial, Jean-Philippe; Park, Sophie; Vieira Dos Santos, Christina; Kaphan, Eléonore; Berthon, Céline; Stamatoullas, Aspasia; Delhommeau, François; Abermil, Nassera; Braun, Thorsten; Sapena, Rosa; Lusina, Daniel; Renneville, Aline; Adès, Lionel; Raynaud, Sophie; Fenaux, Pierre.
Afiliação
  • Drevon L; Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris (APHP), University Paris Diderot (Paris 7), Paris, France.
  • Marceau A; Centre Hospitalier Régional Universitaire (CHRU) de Lille, Lille, France.
  • Maarek O; Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris (APHP), University Paris Diderot (Paris 7), Paris, France.
  • Cuccuini W; Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris (APHP), University Paris Diderot (Paris 7), Paris, France.
  • Clappier E; Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris (APHP), University Paris Diderot (Paris 7), Paris, France.
  • Eclache V; Hôpital Avicenne, APHP, University Paris 13, Bobigny, France.
  • Cluzeau T; Centre Hospitalier Universitaire (CHU) de Nice, Nice, France.
  • Richez V; Centre Hospitalier Universitaire (CHU) de Nice, Nice, France.
  • Berkaoui I; Centre Hospitalier Universitaire (CHU) de Nice, Nice, France.
  • Dimicoli-Salazar S; CHU de Bordeaux, Bordeaux, France.
  • Bidet A; CHU de Bordeaux, Bordeaux, France.
  • Vial JP; CHU de Bordeaux, Bordeaux, France.
  • Park S; CHU Grenoble Alpes, Grenoble, France.
  • Vieira Dos Santos C; CHU Grenoble Alpes, Grenoble, France.
  • Kaphan E; CHU Grenoble Alpes, Grenoble, France.
  • Berthon C; Centre Hospitalier Régional Universitaire (CHRU) de Lille, Lille, France.
  • Stamatoullas A; CHU de Rouen, Rouen, France.
  • Delhommeau F; Hôpital Saint-Antoine, APHP, University Pierre et Marie Curie (Paris 6), Paris, France.
  • Abermil N; Hôpital Saint-Antoine, APHP, University Pierre et Marie Curie (Paris 6), Paris, France.
  • Braun T; Hôpital Avicenne, APHP, University Paris 13, Bobigny, France.
  • Sapena R; GFM (Groupe Francophone des Myélodysplasies), Hôpital Saint-Louis, Paris, France.
  • Lusina D; Hôpital Avicenne, APHP, University Paris 13, Bobigny, France.
  • Renneville A; Centre Hospitalier Régional Universitaire (CHRU) de Lille, Lille, France.
  • Adès L; Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris (APHP), University Paris Diderot (Paris 7), Paris, France.
  • Raynaud S; Centre Hospitalier Universitaire (CHU) de Nice, Nice, France.
  • Fenaux P; Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris (APHP), University Paris Diderot (Paris 7), Paris, France.
Br J Haematol ; 182(6): 843-850, 2018 09.
Article em En | MEDLINE | ID: mdl-30004110
ABSTRACT
Isolated trisomy 8 (+8) is a frequent cytogenetic abnormality in the myelodysplastic syndromes (MDS), but its characteristics are poorly reported. We performed a retrospective study of 138 MDS patients with isolated +8, classified or reclassified as MDS (excluding MDS/myeloproliferative neoplasm). Myeloproliferative (MP) features were defined by the repeated presence of one of the following white blood cell count >10 × 109 /l, myelemia (presence of circulating immature granulocytes with a predominance of more mature forms) >2%, palpable splenomegaly. Fifty-four patients (39·1%) had MP features 28 at diagnosis, 26 were acquired during evolution. MP forms had more EZH2 (33·3% vs. 12·0% in non-MP, P = 0·047), ASXL1 (66·7% vs. 42·3%, P = 0·048) and STAG2 mutations (77·8% vs. 21·7%, P = 0·006). Median event-free survival (EFS) and overall survival (OS) were 25 and 27 months for patients with MP features at diagnosis, versus 28 (P = 0·15) and 39 months (P = 0·085) for those without MP features, respectively. Among the 57 patients who received hypomethylating agent (HMA), OS was lower in MP cases (13 months vs. 23 months in non-MP cases, P = 0.02). In conclusion, MP features are frequent in MDS with isolated +8. MP forms had more EZH2, ASXL1 and STAG2 mutations, responded poorly to HMA, and tended to have poorer survival than non-MP forms.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Trissomia / Síndromes Mielodisplásicas / Transtornos Mieloproliferativos Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: Br J Haematol Ano de publicação: 2018 Tipo de documento: Article País de afiliação: França

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Trissomia / Síndromes Mielodisplásicas / Transtornos Mieloproliferativos Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: Br J Haematol Ano de publicação: 2018 Tipo de documento: Article País de afiliação: França